Thermo Fisher Scientific Releases 2023 Corporate Social Responsibility Report

 

  Report highlights company's commitments to all of its stakeholders and society  

 

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today released its 2023 Corporate Social Responsibility (CSR) report, which provides an overview of the company, its CSR priorities and the progress enabled by its more than 120,000 colleagues.

 

�Thermo Fisher is driven by a profound Mission to enable our customers to make the world healthier, cleaner, and safer," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "We also understand our obligation goes beyond enabling our customers' success and extends to making the world a better place by supporting our communities, being a good steward of our planet and creating a great work environment for our colleagues. I am proud of what we've accomplished so far and deeply grateful to our global team for their passion for fulfilling our Mission and delivering on our commitments to society."

 

Highlights of the report include:

 

  Communities  

 
  • Collectively volunteered more than 100,000 hours to support communities around the world.
  •  
  • Reached more than 60,000 students through the Thermo Fisher Scientific Junior Innovators Challenge in partnership with the Society for Science, the premier STEM competition for middle schoolers in the U.S.
  •  
  • Established collaborations with the National Quality Minority Forum, to increase diversity in clinical trials, and Project HOPE, to advance health equity among HIV-positive youth in sub-Saharan Africa.
  •  

  Environment  

 
  • Achieved key milestones toward the company's goal of net-zero emissions by 2050, including the sourcing 41% of global electricity from renewable energy.
  •  
  • Announced a new agreement to power over half of Thermo Fisher's European footprint with 100% renewable energy by 2025.
  •  
  • Established new commitment to achieve 80% renewable electricity utilization globally by 2030.
  •  

  Colleagues  

 
  • Advanced our vibrant and inclusive culture where colleagues' unique backgrounds and perspectives are embraced.
  •  
  • Continued to develop the workforce, including launching new training programs for emerging technologies and an internal generative AI platform.
  •  
  • Enhanced global access to wellness resources.
  •  

In reporting its CSR progress, the company considers internationally recognized standards, guidelines and reference frameworks, including the Global Reporting Initiative (GRI) Standards, the IFRS Foundation's SASB Standards, the Task Force on Climate-related Financial Disclosures (TCFD) and the United Nations Sustainable Development Goals (SDGs). Thermo Fisher makes additional topic-specific ESG data available to key stakeholders through its annual CDP report and voluntary disclosure of EEO-1 information.

 

Learn more at www.thermofisher.com/CSR .

 

  About Thermo Fisher Scientific  

 

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com .

 

  

  

Media:
Sandy Pound
Thermo Fisher Scientific
781-622-1223
sandy.pound@thermofisher.com  

 

Investors:
Rafael Tejada
Thermo Fisher Scientific
781-622-1356
rafael.tejada@thermofisher.com  

 

News Provided by Business Wire via QuoteMedia

TMO
The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×